Toviaz (fesoterodine fumarate) NDC 0069-0242

NDC codes

FDA NDC Directory

Product NDC (as listed)0069-0242Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00069-0242Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0069-0242-30	00069024230	30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0069-0242-30)Marketed from Oct 31, 2008

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Toviaz
Generic name (nonproprietary): fesoterodine fumarate
Active ingredients: Fesoterodine fumarate — 4 mg/1
Dosage form: Tablet, Film coated, Extended release
Route: Oral
Labeler: Pfizer Laboratories Div Pfizer Inc
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 022030
Marketing start: Oct 31, 2008
Listing expires: Dec 31, 2027
Identifiers: Product ID 0069-0242_ca2031f1-5425-4d31-bf14-c865ec4e89b7SPL ID ca2031f1-5425-4d31-bf14-c865ec4e89b7SPL set ID 5be745f0-8ae7-4c3c-9962-37d6263326f1RxCUI 810071, 810075, 810077, 810079UNII EOS72165S7UPC 0300690242309, 0300690244303

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400069024230 followed by a unit qualifier and the quantity

Package 00069-0242-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 7, 2026.

Indications (excerpt from the label)

Toviaz is indicated for the treatment of: • Overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. ( 1.1 ) • Neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older and weighing greater than 25 kg. ( 1.2 ) 1.1 Adult Overactive Bladder Toviaz is indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. 1.2 Pediatric Neurogenic Detrusor Overactivity Toviaz is indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older with a body weight greater than 25 kg.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 022030

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 022030
Product	Strength	Form · route	Labeler	Product NDC
Toviazfesoterodine fumarate	Fesoterodine fumarate 8 mg/1	Tablet, Film coated, Extended releaseOral	Pfizer Laboratories Div Pfizer Inc	0069-0244